Omnihealth Practice

HEMATOLOGY

The real-world use of ixazomib achieved stable disease for nearly 3 years, longer than in clinical trial

24 Mar 2021

Real-world analysis found ixazomib triple therapy effective in the management of relapsed/refractory multiple myeloma

28 Feb 2021

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

31 Dec 2020

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

31 Dec 2020

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma

30 Dec 2020

Recent advances in management of chronic lymphocytic leukemia patients with a novel kinase inhibitor

29 Oct 2020

The use of daratumumab in multiple myeloma: Developing novel immunotherapy strategies to prolong survival

31 Aug 2020

Advanced-stage Hodgkin lymphoma in an elderly patient: A case report highlighting the efficacy of brentuximab vedotin treatment

30 Jun 2020

Ixazomib in treatment of relapsed/refractory multiple myeloma: A case review from Hong Kong

29 Apr 2020

Ride with the tide: Treatment strategies for B-cell non-hodgkin lymphoma

30 Oct 2019

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

Multiple myeloma (MM) is a plasma cell malignancy with approximately 150,000 new cases globally each year.1 In 2016, approximately 270 new cases were reported in Hong Kong.1 As the second most frequent hematological disease worldwide, MM accounts for 0.9% of all new cancer cases and 1.1% of all canc

31 Dec 2020

Dr. Wong, Siu-Ming Raymond

Head of Division of Haematology,
Department of Medicine & Therapeutics,
Faculty of Medicine,
The Chinese University of Hong Kong

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

The combination treatment approach of chemotherapy and radiotherapy has significantly improved the survival outcomes of patients with Hodgkin lymphoma (HL) over the past several decades.1 Whereas the conventional frontline therapies, such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), c

31 Dec 2020

Dr. Law, Man-Fai

Division of Haematology,
Department of Medicine & Therapeutics,
Prince of Wales Hospital,
Hong Kong

EHA25

11 - 21 June 2020 |

Virtual

Real-world analysis found ixazomib triple therapy effective in the management of relapsed/refractory multiple myeloma

HEMATOLOGY ONCOLOGY

28 Feb 2021

Professor Graham Jackson

Professor of Clinical Hematology,
Freeman Hospital,
The Newcastle Upon Tyne Hospitals,
NHS Foundation Trust, United Kingdom

The real-world use of ixazomib achieved stable disease for nearly 3 years, longer than in clinical trial

Multiple myeloma (MM) is the second most common hematological malignancy and is associated with significant morbidity due to its end-organ destruction.1 Despite significant treatment advances in the past couple decades, MM remains an incurable malignancy with most patients eventually experience rela

24 Mar 2021

Dr. Chau, Ling-Kit Nicholas

Specialist in Hematology and Hematological Oncology,

Pamela Youde Nethersole Eastern Hospital

Novel disease-risk stratification system provides a finer prediction of survival following stem-cell transplantation for patients with hematologic malignancies

Hematologic malignancy is the 10th most common cancer in Hong Kong with more than 1,000 new cases diagnosed each year.1 While most of the other cancers affect mainly old people, sufferers of hematologic malignancies can be at any age from newborns to the elderly.1 Although there is a broad range of

09 Apr 2021

FDA greenlit crizotinib for children and young adults with relapsed or refractory anaplastic large cell lymphoma

As a rare disease that represents only 10-15% of all non-Hodgkin lymphomas (NHL) in children, systemic anaplastic large cell lymphoma (ALCL) remains a clinical challenge since optimal treatments are yet to be established.1,2 Despite the utilization of reportedly successful chemotherapy at various pu

09 Apr 2021